Averting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project
Mult Scler Relat Disord. 2021 Jun 30;54:103107. doi: 10.1016/j.msard.2021.103107 PDf is behind a paywall
Michela Tinelli 1, Maura Pugliatti 2, Andreea Antonovici 3, Bettina Hausmann 3, Kerstin Hellwig 4, Vinciane Quoidbach 5, Per Soelberg Sørensen 6
Previous conference presentation by similar authors, similar title
Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019
- Overview MS and vitamin D
- An opportunity - use Vitamin D to treat Multiple Sclerosis (has been used for 14 years) - Feb 2022
- Multiple Sclerosis treated when use high doses of vitamin D – meta-analysis May 2018
- Multiple Sclerosis: 10 percent fewer relapses for each 10 ng higher level of vitamin D – Meta-analysis April 2020
- Multiple Sclerosis: number needed to treat with vitamin D may be as low as 1.3 – Meta-analysis Oct 2013
- Multiple Sclerosis more likely if poor vitamin D genes - 22nd study – Aug 2017
- Multiple Sclerosis relapses cut in half by 100,000 IU of Vitamin D every 2 weeks– RCT 2019
UV and Sunshine reduces MS risk
- Multiple Sclerosis 2X more likely if low winter UV – June 2018
- Multiple Sclerosis half as likely if get plenty of sunshine (not a news item) – March 2018
Other things also help
- Multiple Sclerosis treated by 50,000 IU Vitamin D bi-weekly plus Omega-3 – RCT July 2018
- Multiple Sclerosis 40 percent less likely if consume tinned fish (Vitamin D and Omega-3) – Sept 2019
- Resveratrol treats Multiple Sclerosis and other autoimmune diseases – many studies
- Not a single case of multiple sclerosis in 15,000,000 people (plant-based diets)
High Dose Vitamin D and cofactors
- Coimbra protocol using high-dose Vitamin D is safe – April 2022
- The use of high dose Vitamin D (Coimbra Protocol) for multiple sclerosis in Germany – 2019
- Comparing High-dose vitamin D therapies MS and other health problems
Number of MS studies which are also in other categories
-
22 studies in Genetics - genes can restrict Vitamin D getting to the blood and to the cells 14 studies in Vitamin D Receptor - gene which restricts D from getting to the cells 7 studies in Vitamin D Binding Protein - gene which restricts D from getting to the cells 21 studies in Ultraviolet light - may be even better than Vitamin D in preventing and treating MS 9 studies in Omega-3 - which helps Vitamin D prevent and treat MS
- Rate of vitamin D supplementation by Blacks increases 16X after getting Multiple Sclerosis – Feb 2018
- Multiple Sclerosis 42X more likely if light brown skin and smoke (both associated with low vitamin D) – July 2020
- Multiple Sclerosis patients had fewer COVID-19 problems (Note: many MSers take Vitamin D) – April 30, 2021
- UK people with Multiple Sclerosis are 3X more likely to take Vitamin D - Oct 2020
- Multiple Sclerosis relapses cut in half by 100,000 IU of Vitamin D every 2 weeks– RCT 2019
Background and purpose: The recent report on Value-of-Treatment (VoT) project highlights the need for early diagnosis-intervention, integrated, seamless care underpinning timely care pathways and access to best treatments. The VoT-multiple-sclerosis (MS) economic case study analysis aimed to estimate the effectiveness/cost-effectiveness of both early treatment and reducing MS risk factors (e.g. smoking and vitamin D insufficiency).
Methods: A series of decision analytical modellings were developed and applied to estimate the cost-effectiveness of: (1) reducing the conversion from clinically-isolated-syndrome (CIS) to clinically-definite-MS (CDMS); (2) smoking cessation and increase of 25 hydroxyvitamin D (25(OH)D) serum level. Both (1) and (2) considered socioeconomic impact on averted MS disability progression. Costs were reported for societal and healthcare provider perspectives (pending on data across nations; Euros). Effectiveness was expressed as Quality-Adjusted-Life-Years (QALYs) gains. Long term (25, 30, 40,50-years) and short (one-year) timelines were considered for (1) and (2), respectively.
Results: Early treatment was cost-effective for the health care provider and both cost-effective/cost-saving for the society across time-horizons and nations. Smoking cessation and an increase of 25(OH)D in MS patients were both cost-effective/cost-saving across nations.
Conclusions: To the best of our knowledge, our work provides the first economic evidence to base appropriate public health interventions to reduce the MS burden in Europe.
Title change made June 2022 caused the visitor count to reset.
There have actually been3278 visitors to this page since it was originally made Printer Friendly Follow this page for updates2458 visitors, last modified 28 Jun, 2022,